Titre : Politique publique

Politique publique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Workers' Compensation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Politique publique : Questions médicales les plus fréquentes", "headline": "Politique publique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Politique publique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-16", "dateModified": "2025-03-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Politique publique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Politiques de régulation sociale", "url": "https://questionsmedicales.fr/mesh/D011049", "about": { "@type": "MedicalCondition", "name": "Politiques de régulation sociale", "code": { "@type": "MedicalCode", "code": "D011049", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Politique de planification familiale", "alternateName": "Family Planning Policy", "url": "https://questionsmedicales.fr/mesh/D016656", "about": { "@type": "MedicalCondition", "name": "Politique de planification familiale", "code": { "@type": "MedicalCode", "code": "D016656", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.214" } } }, { "@type": "MedicalWebPage", "name": "Politique de santé", "alternateName": "Health Policy", "url": "https://questionsmedicales.fr/mesh/D006291", "about": { "@type": "MedicalCondition", "name": "Politique de santé", "code": { "@type": "MedicalCode", "code": "D006291", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Politique nutritionnelle", "alternateName": "Nutrition Policy", "url": "https://questionsmedicales.fr/mesh/D018673", "about": { "@type": "MedicalCondition", "name": "Politique nutritionnelle", "code": { "@type": "MedicalCode", "code": "D018673", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.650" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Apports nutritionnels recommandés", "alternateName": "Recommended Dietary Allowances", "url": "https://questionsmedicales.fr/mesh/D064167", "about": { "@type": "MedicalCondition", "name": "Apports nutritionnels recommandés", "code": { "@type": "MedicalCode", "code": "D064167", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.650.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Apports nutritionnels recommandés", "alternateName": "Recommended Dietary Allowances", "url": "https://questionsmedicales.fr/mesh/D064167", "about": { "@type": "MedicalCondition", "name": "Apports nutritionnels recommandés", "code": { "@type": "MedicalCode", "code": "D064167", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.650.500" } } }, { "@type": "MedicalWebPage", "name": "Contrôle du tabac", "alternateName": "Tobacco Control", "url": "https://questionsmedicales.fr/mesh/D000092843", "about": { "@type": "MedicalCondition", "name": "Contrôle du tabac", "code": { "@type": "MedicalCode", "code": "D000092843", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Politique anti-tabac", "alternateName": "Smoke-Free Policy", "url": "https://questionsmedicales.fr/mesh/D061845", "about": { "@type": "MedicalCondition", "name": "Politique anti-tabac", "code": { "@type": "MedicalCode", "code": "D061845", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.500" } } }, { "@type": "MedicalWebPage", "name": "Prévention du fait de fumer", "alternateName": "Smoking Prevention", "url": "https://questionsmedicales.fr/mesh/D000074606", "about": { "@type": "MedicalCondition", "name": "Prévention du fait de fumer", "code": { "@type": "MedicalCode", "code": "D000074606", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.750" } } } ] }, { "@type": "MedicalWebPage", "name": "Politique anti-tabac", "alternateName": "Smoke-Free Policy", "url": "https://questionsmedicales.fr/mesh/D061845", "about": { "@type": "MedicalCondition", "name": "Politique anti-tabac", "code": { "@type": "MedicalCode", "code": "D061845", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.500" } } }, { "@type": "MedicalWebPage", "name": "Prévention du fait de fumer", "alternateName": "Smoking Prevention", "url": "https://questionsmedicales.fr/mesh/D000074606", "about": { "@type": "MedicalCondition", "name": "Prévention du fait de fumer", "code": { "@type": "MedicalCode", "code": "D000074606", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N03.623.500.608.428.825.750" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Politique publique", "alternateName": "Public Policy", "code": { "@type": "MedicalCode", "code": "D011640", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Krystyna Kongats", "url": "https://questionsmedicales.fr/author/Krystyna%20Kongats", "affiliation": { "@type": "Organization", "name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Jennifer Ann McGetrick", "url": "https://questionsmedicales.fr/author/Jennifer%20Ann%20McGetrick", "affiliation": { "@type": "Organization", "name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Kim D Raine", "url": "https://questionsmedicales.fr/author/Kim%20D%20Raine", "affiliation": { "@type": "Organization", "name": "School of Public Health, University of Alberta, Edmonton Clinic Health Academy, Edmonton, Alberta, Canada." } }, { "@type": "Person", "name": "Sonja Grelle", "url": "https://questionsmedicales.fr/author/Sonja%20Grelle", "affiliation": { "@type": "Organization", "name": "Faculty of Psychology, Ruhr University Bochum." } }, { "@type": "Person", "name": "Wilhelm Hofmann", "url": "https://questionsmedicales.fr/author/Wilhelm%20Hofmann", "affiliation": { "@type": "Organization", "name": "Faculty of Psychology, Ruhr University Bochum." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Heterologous Vector-mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector-Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines.", "datePublished": "2023-03-19", "url": "https://questionsmedicales.fr/article/36992285", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/vaccines11030701" } }, { "@type": "ScholarlyArticle", "name": "A Single Dose of ChAdOx1 nCoV-19 Vaccine Elicits High Antibody Responses in Individuals with Prior SARS-CoV-2 Infection Comparable to That of Two-Dose-Vaccinated, SARS-CoV-2-Infection-Naïve Individuals: A Longitudinal Study in Ethiopian Health Workers.", "datePublished": "2022-05-27", "url": "https://questionsmedicales.fr/article/35746467", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/vaccines10060859" } }, { "@type": "ScholarlyArticle", "name": "Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.", "datePublished": "2022-09-21", "url": "https://questionsmedicales.fr/article/36152671", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/S1473-3099(22)00578-3" } }, { "@type": "ScholarlyArticle", "name": "COVID-19 seroprevalence among local authority workers from Orléans Métropole, the Community of Communes of the Terres du Val de Loire, the local public service management centre of the Loiret department and the Region Centre Val de Loire: a prospective epidemiological study.", "datePublished": "2023-05-22", "url": "https://questionsmedicales.fr/article/37217267", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2022-066504" } }, { "@type": "ScholarlyArticle", "name": "Increasing antiretroviral therapy adherence and retention in care among adults living with HIV in Philadelphia: a study protocol for a stepped-wedge cluster-randomised type 2 hybrid effectiveness-implementation trial of managed problem-solving plus (MAPS+) delivered by community health workers.", "datePublished": "2023-10-21", "url": "https://questionsmedicales.fr/article/37865411", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1136/bmjopen-2023-079585" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Organisations et économie des soins de santé", "item": "https://questionsmedicales.fr/mesh/D004472" }, { "@type": "ListItem", "position": 3, "name": "Politique (principe)", "item": "https://questionsmedicales.fr/mesh/D057766" }, { "@type": "ListItem", "position": 4, "name": "Politiques de régulation sociale", "item": "https://questionsmedicales.fr/mesh/D011049" }, { "@type": "ListItem", "position": 5, "name": "Politique publique", "item": "https://questionsmedicales.fr/mesh/D011640" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Politique publique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Politique publique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Politique publique", "description": "Comment évaluer l'impact d'une politique publique en santé ?\nQuels outils sont utilisés pour le diagnostic des politiques ?\nQuelles sont les méthodes d'analyse des politiques publiques ?\nComment identifier les besoins de santé dans une communauté ?\nQuel rôle joue la recherche dans le diagnostic des politiques ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Workers'+Compensation&page=952#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Politique publique", "description": "Quels symptômes indiquent un échec de la politique publique ?\nComment mesurer les symptômes de l'inefficacité des politiques ?\nQuels indicateurs de santé révèlent des problèmes systémiques ?\nComment les symptômes sociaux affectent-ils la santé publique ?\nQuels symptômes peuvent signaler un besoin de réforme ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Workers'+Compensation&page=952#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Politique publique", "description": "Quelles stratégies de prévention sont efficaces en politique publique ?\nComment évaluer l'efficacité des programmes de prévention ?\nQuels obstacles à la prévention sont souvent rencontrés ?\nComment les politiques publiques peuvent-elles promouvoir la prévention ?\nQuel rôle joue l'éducation dans la prévention des maladies ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Workers'+Compensation&page=952#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Politique publique", "description": "Comment les politiques influencent-elles les traitements disponibles ?\nQuels traitements sont souvent négligés par les politiques publiques ?\nComment évaluer l'efficacité des traitements en politique publique ?\nQuel est l'impact des politiques sur les traitements préventifs ?\nComment les politiques de santé affectent-elles les traitements psychologiques ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Workers'+Compensation&page=952#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Politique publique", "description": "Quelles complications peuvent résulter d'une mauvaise politique de santé ?\nComment les complications de santé sont-elles liées aux politiques publiques ?\nQuels sont les effets à long terme d'une politique de santé défaillante ?\nComment prévenir les complications liées aux politiques de santé ?\nQuel rôle jouent les données dans la prévention des complications ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Workers'+Compensation&page=952#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Politique publique", "description": "Quels facteurs de risque sont souvent négligés par les politiques ?\nComment les politiques peuvent-elles réduire les facteurs de risque ?\nQuel impact a l'environnement sur les facteurs de risque ?\nComment les politiques de santé abordent-elles les facteurs de risque ?\nQuels sont les facteurs de risque liés aux comportements ?", "url": "https://questionsmedicales.fr/mesh/D011640?mesh_terms=Workers'+Compensation&page=952#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact d'une politique publique en santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact se mesure par des indicateurs de santé, des études d'impact et des analyses de données." } }, { "@type": "Question", "name": "Quels outils sont utilisés pour le diagnostic des politiques ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des enquêtes, des analyses statistiques et des études de cas sont couramment utilisés." } }, { "@type": "Question", "name": "Quelles sont les méthodes d'analyse des politiques publiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les méthodes incluent l'analyse qualitative, quantitative et l'analyse coût-bénéfice." } }, { "@type": "Question", "name": "Comment identifier les besoins de santé dans une communauté ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Par des enquêtes, des focus groups et l'analyse des données de santé existantes." } }, { "@type": "Question", "name": "Quel rôle joue la recherche dans le diagnostic des politiques ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La recherche fournit des données probantes pour orienter les décisions politiques et évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels symptômes indiquent un échec de la politique publique ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des inégalités de santé croissantes et une augmentation des maladies évitables peuvent indiquer un échec." } }, { "@type": "Question", "name": "Comment mesurer les symptômes de l'inefficacité des politiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "En analysant les taux de morbidité, mortalité et l'accès aux soins de santé." } }, { "@type": "Question", "name": "Quels indicateurs de santé révèlent des problèmes systémiques ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les taux de vaccination, d'obésité et de maladies chroniques sont des indicateurs clés." } }, { "@type": "Question", "name": "Comment les symptômes sociaux affectent-ils la santé publique ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des problèmes comme la pauvreté et le chômage aggravent les conditions de santé et l'accès aux soins." } }, { "@type": "Question", "name": "Quels symptômes peuvent signaler un besoin de réforme ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Une hausse des plaintes des citoyens et des résultats de santé dégradés peuvent signaler ce besoin." } }, { "@type": "Question", "name": "Quelles stratégies de prévention sont efficaces en politique publique ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les campagnes de sensibilisation, les programmes de vaccination et l'éducation à la santé." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des programmes de prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Par des études d'impact, des indicateurs de santé et des analyses de coûts." } }, { "@type": "Question", "name": "Quels obstacles à la prévention sont souvent rencontrés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Le manque de financement, l'accès limité aux soins et la désinformation sont des obstacles majeurs." } }, { "@type": "Question", "name": "Comment les politiques publiques peuvent-elles promouvoir la prévention ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "En intégrant des programmes de prévention dans les systèmes de santé et en finançant des initiatives." } }, { "@type": "Question", "name": "Quel rôle joue l'éducation dans la prévention des maladies ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "L'éducation sensibilise la population aux comportements sains et aux risques de maladies." } }, { "@type": "Question", "name": "Comment les politiques influencent-elles les traitements disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les politiques déterminent le financement, l'accès et les protocoles de traitement en santé." } }, { "@type": "Question", "name": "Quels traitements sont souvent négligés par les politiques publiques ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements pour les maladies rares et les soins palliatifs sont souvent sous-financés." } }, { "@type": "Question", "name": "Comment évaluer l'efficacité des traitements en politique publique ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Par des études cliniques, des revues systématiques et des analyses de coût-efficacité." } }, { "@type": "Question", "name": "Quel est l'impact des politiques sur les traitements préventifs ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les politiques favorisent l'accès aux vaccinations et dépistages, réduisant ainsi les maladies." } }, { "@type": "Question", "name": "Comment les politiques de santé affectent-elles les traitements psychologiques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Elles influencent le financement et l'accès aux soins de santé mentale, souvent négligés." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter d'une mauvaise politique de santé ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des inégalités de santé, une augmentation des maladies chroniques et un accès limité aux soins." } }, { "@type": "Question", "name": "Comment les complications de santé sont-elles liées aux politiques publiques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des politiques inefficaces peuvent aggraver les conditions de santé et limiter l'accès aux traitements." } }, { "@type": "Question", "name": "Quels sont les effets à long terme d'une politique de santé défaillante ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une augmentation des coûts de santé, une détérioration de la santé publique et des inégalités croissantes." } }, { "@type": "Question", "name": "Comment prévenir les complications liées aux politiques de santé ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "En évaluant régulièrement les politiques et en adaptant les programmes aux besoins de la population." } }, { "@type": "Question", "name": "Quel rôle jouent les données dans la prévention des complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les données aident à identifier les problèmes, à évaluer les politiques et à orienter les interventions." } }, { "@type": "Question", "name": "Quels facteurs de risque sont souvent négligés par les politiques ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les déterminants sociaux de la santé, comme la pauvreté et l'éducation, sont souvent sous-estimés." } }, { "@type": "Question", "name": "Comment les politiques peuvent-elles réduire les facteurs de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "En promouvant des environnements sains, l'éducation et l'accès aux soins préventifs." } }, { "@type": "Question", "name": "Quel impact a l'environnement sur les facteurs de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement pollué ou peu sûr augmente les risques de maladies et affecte la santé publique." } }, { "@type": "Question", "name": "Comment les politiques de santé abordent-elles les facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Elles intègrent des stratégies de prévention et d'éducation pour réduire les risques de maladies." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque liés aux comportements ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, l'alimentation malsaine et le manque d'activité physique sont des facteurs clés." } } ] } ] }

Sources (9520 au total)

Heterologous Vector-mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vector-Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines.

Longitudinal humoral SARS-CoV-2 (severe acute respiratory syndrome coronavirus type 2) immunity for up to 15 months due to vaccination, the efficacy of vaccination strategies (homologous, vector-vecto... In this study, 103 individuals vaccinated against SARS-CoV-2 were enrolled to examine their anti-SARS-CoV-2 anti-N- and anti-RBD/S1-Ig levels. A total of 415 blood samples in lithium heparin tubes wer... All participants demonstrated a humoral immune response, among whom no values decreased below the positivity cutoff. Five to six months after the third vaccination, three participants showed anti-RBD/... Sustained long-term humoral immunity was observed, indicating the superiority of a heterologous mRNA-/vector-based combination compared to pure vector-based vaccination. There was longevity of anti-RB...

A Single Dose of ChAdOx1 nCoV-19 Vaccine Elicits High Antibody Responses in Individuals with Prior SARS-CoV-2 Infection Comparable to That of Two-Dose-Vaccinated, SARS-CoV-2-Infection-Naïve Individuals: A Longitudinal Study in Ethiopian Health Workers.

Single-dose COVID-19 vaccines, mostly mRNA-based vaccines, are shown to induce robust antibody responses in individuals who were previously infected with SARS-CoV-2, suggesting the sufficiency of a si...

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.

There is a paucity of data on vaccine-induced or infection-induced (hybrid or natural) immunity against omicron (B.1.1.529) subvariant BA.2, particularly in comparing the effects of previous SARS-CoV-... We conducted a test-negative case-control study among health-care workers aged 18 years or older who were tested for SARS-CoV-2 in Quebec, Canada, between March 27 and June 4, 2022, when BA.2 was the ... 258 007 SARS-CoV-2 tests were done during the study period. Among those with a valid result and that met the inclusion criteria, there were 37 732 presumed BA.2 cases (2521 [6·7%] reinfections followi... Health-care workers who had received two doses of mRNA vaccine and had previous BA.1 infection were subsequently well protected for a prolonged period against BA.2 reinfection, with a third vaccine do... Ministère de la Santé et des Services Sociaux du Québec....

COVID-19 seroprevalence among local authority workers from Orléans Métropole, the Community of Communes of the Terres du Val de Loire, the local public service management centre of the Loiret department and the Region Centre Val de Loire: a prospective epidemiological study.

To evaluate the SARS-CoV-2 seroprevalence among local authority workers, depending on their position and potential interaction with the public.... A cohort of volunteer participants was recruited among local authority workers of the Centre Val de Loire region in France, to be tested using a rapid serological test (COVID-PRESTO). The collected da... The seroprevalence of SARS-CoV-2 among local authority workers was estimated at 3.04%. No significant difference could be observed according to the position held by the workers and whether they were o... Contact with members of the public was not a critical parameter for SARS-CoV-2 seroprevalence as long as protective measures are applied. Among the population included in the study, childcare workers ... NCT04387968....

Increasing antiretroviral therapy adherence and retention in care among adults living with HIV in Philadelphia: a study protocol for a stepped-wedge cluster-randomised type 2 hybrid effectiveness-implementation trial of managed problem-solving plus (MAPS+) delivered by community health workers.

To end the HIV epidemic in Philadelphia, implementation of evidence-based practices (EBP) to increase viral suppression and retention in HIV care is critical. Managed problem solving (MAPS), an EBP fo... This manuscript describes the protocol for a stepped-wedge cluster-randomised type 2 hybrid effectiveness-implementation trial in 10 clinics in Philadelphia. This research incorporates innovative appr... The institutional review board (IRB) at the city of Philadelphia serves as the primary IRB; initial approval was granted on 21 December 2020. The University of Pennsylvania and Northwestern University... NCT04560621....

[Mental health of Guatemalan health care workers during the COVID-19 pandemic: baseline findings from the HEROES cohort studySaúde mental dos trabalhadores da saúde guatemaltecos durante a pandemia de COVID-19: constatações basais do estudo da coorte HEROES].

To assess the baseline prevalence of mental health conditions and associated exposures in a cohort of health care workers (HCWs) in Guatemala.... We analyzed baseline information from the 2020 Web-based COVID-19 Health Care Workers Study (HEROES)-Guatemala. Outcomes included mental distress and depressive symptoms. Exposures included COVID-19 e... Of the 1801 HCWs who accepted to participate, 1522 (84.5%) completed the questionnaire; 1014 (66.8%) were women. Among the participants, 59.1% (95% confidence interval [CI] = 56.6, 61.5) screened posi... Mental health conditions are highly prevalent among Guatemalan....

A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study.

With SARS-CoV-2 antibody tests on the market, healthcare providers must be confident that they can use the results to provide actionable information to understand the characteristics and dynamics of t... We retrospectively evaluated antibody responses via multiplex assays in a sample of 538 asymptomatic HCWs with a documented complete vaccination cycle of 3 doses of mRNA vaccination and no previous hi... A significant difference in age between HCWs who were positive and negative for anti-N IgG was observed. For anti-S2 IgG, a significant difference between HCWs who were negative and positive compared ... Most anti-N positive HCWs showed antibodies against the S2 domain and were young subjects. Therefore, the authors suggest that including the anti-SARS-CoV-2-S2 in antibody profiles can serve as a comp...

Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial.

Health-care providers and front-line workers are at risk of contracting Ebola virus disease during an Ebola virus outbreak and consequently of becoming drivers of the disease. We aimed to assess the l... This open-label, single-centre, randomised, phase 2 trial was conducted at one study site within a hospital in Boende, Democratic Republic of the Congo. Adult health-care providers and front-line work... Between Dec 18, 2019, and Feb 8, 2020, 699 health-care providers and front-line workers were enrolled and 698 were randomly assigned (350 to group 1 and 348 to group 2 [FAS]); 534 (77%) participants w... Overall, the vaccine regimen and booster dose were well tolerated. A similar and robust humoral immune response was observed for participants boosted 1 year and 2 years after the first dose, supportin... Innovative Medicines Initiative 2 Joint Undertaking and Coalition for Epidemic Preparedness Innovations....

Community-based management of arterial hypertension and cardiovascular risk factors by lay village health workers for people with controlled and uncontrolled blood pressure in rural Lesotho: joint protocol for two cluster-randomized trials within the ComBaCaL cohort study (ComBaCaL aHT Twic 1 and ComBaCaL aHT TwiC 2).

Arterial hypertension (aHT) is a major cause for premature morbidity and mortality. Control rates remain poor, especially in low- and middle-income countries. Task-shifting to lay village health worke... Using the trials within the cohort (TwiCs) design, we are assessing the effectiveness of VHW-led aHT and cardiovascular risk management in two 1:1 cluster-randomized trials nested within the Community... The TwiCs were launched on September 08, 2023. On May 20, 2024, 697 and 750 participants were enrolled in TwiC 1 and TwiC 2. To our knowledge, these TwiCs are the first trials to assess task-shifting ... ClinicalTrials.gov NCT05684055. Registered on January 04, 2023....

Efficacy study comparing a CBT-I developed for shift workers (CBT-I-S) to standard CBT-I (cognitive behavioural therapy for insomnia) on sleep onset latency, total sleep time, subjective sleep quality, and daytime sleepiness: study protocol for a parallel group randomised controlled trial with online therapy groups of seven sessions each.

Shift workers are at an increased risk of developing sleep disorders. The standard therapy recommended for sleep disorders is cognitive behavioural therapy for insomnia (CBT-I). Many of its interventi... A randomised controlled trial with N = 142 will be conducted to compare two conditions: the newly developed therapy manual will be carried out in the experimental group, while cognitive behavioural th... We assume that interventions designed to address depressive mood, anxiety, worry, rumination, dysfunctional thought patterns and attitudes towards sleep will also improve sleep. If this is indeed the ... German Clinical Trials Registry DRKS DRKS00032086 . Registered on August 16, 2023....